GRANULES (GRANULES) Fair Value & Analysis

Healthcare · Market cap ₹205B

G GRANULES GRANULES · NSE

Price₹825.70

Fair Value₹528.27

Upside-36.0%

Quality66/100

Watch GRANULES for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range ₹301.47 – ₹781.73

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +6.2% over the past month.

Price vs Fair Value (12 months)

12‑month range ₹439.35 – ₹825.70 · fair‑value band ₹301.47 – ₹781.73 · the ₹825.70 price screens above the ₹528.27 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

GRANULES (GRANULES) currently trades at ₹825.70, while our model-based Fair Value estimate is ₹528.27 — implying the stock looks roughly 36.0% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, GRANULES generated revenue of ₹53.7B at a net margin of 11.1%. Revenue grew 22.8% year over year. It earns a return on equity of 13.5%. Net debt stands at ₹5.6B. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹53.7B

Revenue growth (YoY) +22.8%

Net margin 11.1%

Return on equity 13.5%

Free cash flow ₹1.2B FY2026

P/E ratio 33.8

More key figures

Operating margin 18.4%

EPS (TTM) ₹24.42

Dividend yield 0.2%

EPS growth (YoY) +31.3%

Net debt ₹5.6B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

GRANULES reported revenue of ₹53.7B in FY2026 versus ₹37.6B in FY2022, a compound +9.3%/yr. Reported net income was ₹6.0B in FY2026, compounding +9.6%/yr from FY2022.

Revenue +9.3%/yr

FY22 ₹37.6B

FY23 ₹45.1B

FY24 ₹45.1B

FY25 ₹44.8B

FY26 ₹53.7B

Net income +9.6%/yr

FY22 ₹4.1B

FY23 ₹5.2B

FY24 ₹4.1B

FY25 ₹5.0B

FY26 ₹6.0B

Is GRANULES fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is GRANULES (GRANULES) undervalued?

As of Jul 3, 2026, our model estimates a fair value of ₹528.27 versus a price of ₹825.70 — about −36% (overvalued). Model-based estimate, not financial advice.

What is the fair value of GRANULES?

Our model-based fair value for GRANULES is ₹528.27 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹825.70.

What is the quality score of GRANULES?

GRANULES has a Quality Score of 66/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of GRANULES (GRANULES)?

GRANULES reported trailing-twelve-month revenue of about ₹53.7B (latest available figure, as of Jul 3, 2026).

What is the net profit margin of GRANULES?

The net profit margin of GRANULES is about 11.1%, meaning it keeps roughly 11.1% of revenue as net income. Based on the latest reported figures.

Does GRANULES pay a dividend?

GRANULES currently shows a dividend yield of about 0.22% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.